ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer

First HER2 directed therapy to show a strong tumor response in this population Data from HER2 mutant cohort of pivotal DESTINY-Lung01 phase 2 trial presented at ESMO and published in The New England Journal of Medicine TOKYO & MUNICH & BASKING RID...

Full "IntellAsia: Resources" article